‘Vitamin B17’: Killing more than cancer

IF 1.7 4区医学 Q2 EMERGENCY MEDICINE Emergency Medicine Australasia Pub Date : 2024-05-28 DOI:10.1111/1742-6723.14450

Ingrid Berling BMed, FACEM, PgD(Clin Tox), PhD, Jared Brown BPharm(Hons), MPH, GradCertClinEpi(ClinTox), Brendan Toy MBBCh, DA, Dip PEC

{"title":"‘Vitamin B17’: Killing more than cancer","authors":"Ingrid Berling BMed, FACEM, PgD(Clin Tox), PhD, Jared Brown BPharm(Hons), MPH, GradCertClinEpi(ClinTox), Brendan Toy MBBCh, DA, Dip PEC","doi":"10.1111/1742-6723.14450","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>Vitamin B17 tablets are sold (online) as an alternative cancer therapy medication. Its use however is not benign, given that it is metabolised into hydrogen cyanide. We aimed to measure the number of calls received by the New South Wales Poisons Information Centre (NSW PIC) regarding Amygdalin exposures.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A retrospective review of all amygdalin/cyanogenic glycoside product ingestion exposure calls to NSW PIC between 2015 and 2022.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>There were 120 unique exposure calls. Eighty-two (68%) were regarding minor exposures, with the remaining 38 (32%) of calls involving patients who had either a signifcant history or symptoms to prompt referral to hospital or were already seeking advice from a treating hospital clinican.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>There is a significant burden of concern generated from the misuse of cyanogenic glycoside products for cancer prevention and treatment, which can result in hospital admission carrying significant health risk and expenditure.</p>\n </section>\n </div>","PeriodicalId":11604,"journal":{"name":"Emergency Medicine Australasia","volume":"36 4","pages":"650-651"},"PeriodicalIF":1.7000,"publicationDate":"2024-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1742-6723.14450","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Emergency Medicine Australasia","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/1742-6723.14450","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"EMERGENCY MEDICINE","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

Vitamin B17 tablets are sold (online) as an alternative cancer therapy medication. Its use however is not benign, given that it is metabolised into hydrogen cyanide. We aimed to measure the number of calls received by the New South Wales Poisons Information Centre (NSW PIC) regarding Amygdalin exposures.

Methods

A retrospective review of all amygdalin/cyanogenic glycoside product ingestion exposure calls to NSW PIC between 2015 and 2022.

Results

There were 120 unique exposure calls. Eighty-two (68%) were regarding minor exposures, with the remaining 38 (32%) of calls involving patients who had either a signifcant history or symptoms to prompt referral to hospital or were already seeking advice from a treating hospital clinican.

Conclusion

There is a significant burden of concern generated from the misuse of cyanogenic glycoside products for cancer prevention and treatment, which can result in hospital admission carrying significant health risk and expenditure.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

维生素 B17杀死的不仅仅是癌症

目的：维生素 B17 药片作为癌症治疗的替代药物在网上销售。然而，由于维生素 B17 会代谢成氰化氢，因此其使用并非无害。我们的目的是测量新南威尔士毒物信息中心（NSW PIC）接到的有关戊二醛暴露的电话数量：方法：对 2015 年至 2022 年期间新南威尔士州毒物信息中心接到的所有杏仁苷/氰苷产品摄入暴露电话进行回顾性审查：结果：共接到 120 个独特的暴露电话。82起（68%）涉及轻微接触，其余38起（32%）涉及有明显病史或症状的患者，这些患者需要转诊至医院，或已经在向治疗医院的临床医生寻求建议：结论：滥用氰苷产品预防和治疗癌症会带来巨大的负担，可能导致患者入院治疗，带来巨大的健康风险和开支。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Emergency Medicine Australasia 医学-急救医学

CiteScore

3.70

自引率

13.00%

发文量

217

审稿时长

6-12 weeks

期刊介绍： Emergency Medicine Australasia is the official journal of the Australasian College for Emergency Medicine (ACEM) and the Australasian Society for Emergency Medicine (ASEM), and publishes original articles dealing with all aspects of clinical practice, research, education and experiences in emergency medicine. Original articles are published under the following sections: Original Research, Paediatric Emergency Medicine, Disaster Medicine, Education and Training, Ethics, International Emergency Medicine, Management and Quality, Medicolegal Matters, Prehospital Care, Public Health, Rural and Remote Care, Technology, Toxicology and Trauma. Accepted papers become the copyright of the journal.